Institutional Ownership Bullish On These US Stocks: $CHEK $OCGN $SNCA

*If You Own CHEK, OCGN, SNCA Then Click Here to Join Our Community Of Traders

The Market Signal was created as a platform to help investors, if you own (NASDAQ:CHEK), (NASDAQ:OCGN) or (NASDAQ: SNCA) and want to join the fastest growing community of investors on the web then sign up to the link below. Members get free access to the best investment tools in the world. Start trading like a pro today. This is a limited time offer so click the link below NOW.

(Click link above or copy, paste and hit enter in your browser for your report)

Check Cap Ltd signs definitive agreement for exercise of warrants at $9.6 Million Gross Proceeds Free-Report/CHEK

(Click link above or copy, paste and hit enter in your browser for your report)

The institutional ownership of the clinical stage medical diagnostics company, Check Cap Ltd (NASDAQ:CHEK) over the previous quarter transformed by 214.30%. On July 23, the company signed definitive agreement with various institutional investors for transaction involving outstanding warrants to an aggregate of 16,054,223 of its ordinary shares. These shares are to be purchased at a discounted price of $0.60 per share.

These warrants that are exercised for purchase were issued on different dates from a period of November 2017 to May 2020. The exercise price ranges from $15.00 to $0.80 per share.

Ocugen Inc granted Orphan Drug Designation for novel gene therapy product candidate Free-Report/OCGN

(Click link above or copy, paste and hit enter in your browser for your report)

The biopharmaceutical company, Ocugen Inc (NASDAQ:OCGN), which specializes in treatment of blindness diseases, reequipped its institutional ownership in last three months by 109.61%. Last week, the company announced that its drug, OCU400 is granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration. This is the third ODD received by the company for its drug.

OCU400 is used for treating retinal degeneration associated with RHO mutation, which is considered a rare genetic disorder. The disorder leads to degeneration and loss of retina cells, which can cause permanent visual impairment or even blindness.

OCU400 is developed as the gene therapy product candidate, claimed to restore retinal reliability as well as function.

Seneca Biopharma Inc provides first quarter business updates Free-Report/SNCA

(Click link above or copy, paste and hit enter in your browser for your report)

Seneca Biopharma Inc (NASDAQ: SNCA)'s institutional ownership since May has jazzed up by 160.83%. The company's ongoing study for sequencing of ovarian tumours as well as validating its process of "reach back" is said to be on track and is expected to be complete by Q2-2020.

Meanwhile, Seneca is also in line with other pharmaceutical companies for development of potential COVID-19 vaccine. Seneca is developing this vaccine in collaboration with former NASA Chief, Dr. Daniel Carter who served in Advanced Materials and Biophysics Branch.

Also, in the times to come, the company will have completed Quantitative Medicine acquisition.

Please email or contact us for any edits or errors relating to this stock market news.

If you would like information on using our press release distribution service aimed at helping investors with the best stocks to buy and how to create your own stock portfolio. We cover the US Stock Market, Canadian Stock Market, the Australian Stock Market and other Stock Market news.

We will get back to you within 24 hours.


The post Institutional Ownership Bullish On These US Stocks: $CHEK $OCGN $SNCA appeared first on The Market Signals.

comtex tracking
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.